Therapeutic effects of Lianhua Qingwen capsules(granules) against pulmonary infections based on data mining in the real world

doi:10.19803/j.1672-8629.2022.02.03

Abstract

Abstract: Objective To find out whether there is any difference in the evaluation of treatment of Lianhua Qingwen capsules(granules) used in patients with pulmonary infections. Methods The data on diagnosis and treatment of patients with pulmonary infections was retrieved from the hospital information system (HIS) of 18 large hospitals in China. A non-randomized control matching design was used to study the therapeutic effect among 2 790 aged- and gender-matched lung infection patients treated with or without Lianhua Qingwen capsules(granules) between September 15, 2004 and December 15, 2015. A propensity score was used to balance confounding factors and to compare the outcomes of regrouped patients. Results After controlling for confounding factors, there was statistically significant difference in Evaluation of treatment between the combined use of Lianhua Qingwen capsules(granules) and the non-combined use. Conclusion Based on the real-world electronic medical data and research methods currently available, it is believed that the use of Lianhua Qingwen capsules(granules) in the treatment of pulmonary infections has a good therapeutic effect. However, the results of this research need to be confirmed by prospective studies.

Key words: Lianhua Qingwen capsules(granules), pulmonary infection, real world, the propensity score

CLC Number:

R969.3

ZHANG Lidan, XIE Yanming, SUN Menghua. Therapeutic effects of Lianhua Qingwen capsules(granules) against pulmonary infections based on data mining in the real world[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 126-129.

References

[1] YU HY, REN XH, QI XX, et al.A retrospective study on the curative effect of abidor, qingfei detox decoction, Lianhua Qingwen capsule and jinye baidu granule on patients with light/ ordinary xinguan pneumonia in a shelter hospital[J]. Pharmacology and Clinics of Chinese Materia Medica(中药药理与临床), 2020, 36(6): 2-6.
[2] WU HG.Enlightenment of Chinese medicine development under the epidemic situation of xinguan pneumonia[J]. Chinese People’s Political Consultative Conference(中国政协), 2020(9): 36-37.
[3] QU JM, CAO B.Guidelines for the diagnosis and treatment of community-acquired pneumonia in Chinese adults (2016 edition)[J]. Chinese Journal of Tuberculosis and Respiratory Diseases(中华结核和呼吸杂志)), 2016, 39(4): 253-279.
[4] ZHANG HY.Causes and clinical of treatment of lung infection[J]. China Practical Medicine(中国实用医药), 2013, 8(25): 40-41.
[5] LU HR.Literature and experimental study on the treatment of pulmonary heat syndrome (lung infection) with qingzao jiufei decoction[D]. Beijing University of Chinese Medicine, 2006.
[6] ZHANG JL, TAN YP.Observation of efficacy of Lianhua Qingwen capsule on lung infection[J].World Chinese Medicine(世界中医药), 2010, 5(3): 158-159.
[7] CUI WW, JIN X, ZHANG YF, et al.Effects of Lianhua Qingwen capsule on IKK/IκB/NF-kappa B signal pathway in the mouse with LPS-induced acute lung injury[J]. Chinese Traditional Patent Medicine(中成药), 2015, 37(5): 953-958.
[8] ZHUANG Y, XIE BT, WENG SX, et al.Discussion on the design method of his "real world" integrated data warehouse[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2011, 36(20): 2880-2882.
[9] GE JB, XU YJ. Internal Medicine(内科学)[M]. 8th ed. Beijing: People's Medical Publishing House, 2014.
[10] World Health Organization.International Statistical Classification of Diseases and Related Health Problems (Revision 10)(疾病和有关健康问题的国际统计分类(第10次修订))[M]. Version 2. Translated by DONG JW. Beijing: People’s Medical Publishing House, 2008.
[11] Hunan University Of Chinese Medicine. National Standard "Clinical Diagnosis and Treatment Terminology of TCM." [EB/OL]. (2019-01-01) [2021-11-25]. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=SNAD&dbname=SNAD&filename=SNAD000001338350&uniplatform=NZKPT&v=TjRX_0fSS4t34YjOYZ5gNMlPSVMc5kdzsUAk1aF3yDTCJfM_Rfr-CRaqMAmfpn1CoQ-uwT-A4RU%3d.
[12] Pharmacy Data.Drug ATC Coding Query System [EB/OL]. [2020-11-25].https://db.yaozh.com/atc/.
[13] NHSA. Notice of the Ministry of Human Resources and Social Security on including the negotiated drugs in class B of the "List of Medicines for National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance" in2019: Health insurance[2019] 46 [EB / OL]. (2019-08-20) [2020-11-25]. https://www.nhsa.gov.cn/art/2019/8/20/art37_1666.html.
[14] NIU QQ, CHEN Y, LIU Y, et al.Efficacy and safety of Lianhua Qingwen capsule for influenza: a systematic review[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2017, 42(8): 1474-1481.
[15] WU YL.Interpretation of Lianhua Qingwen capsule[J]. Guide of China Medicine(中国医药指南), 2005(11): 120-121.
[16] SONG JX, ZHANG ZH, ZHAO SM, et al.Patent information analysis on traditional Chinese medicine for prevention and treatment of COVID-19[J]. Drug Evaluation Research(药物评价研究), 2020, 43(4): 565-590
[17] XIA RY.Investigation and evidence-based evaluation of the influence of traditional Chinese medicine on nonessential antibiotic use in acute lower respiratory tract infection[D]. Beijing University of Chinese Medicine, 2020.
[18] YU XQ, XIE Y, LI JS.Guidelines for the diagnosis and treatment of community-acquired pneumonia in traditional Chinese medicine (2018 Revision)[J]. Journal of Traditional Chinese Medicine(中医杂志), 2019, 60(4): 350-360.
[19] GUO W.Research and application in medical studies of inverse probability weighting based on statistical learning[D]. Naval Medical University, 2018.
[20] WANG LX, XIE YM, YANG W, et al.Clinical efficacy of Shenmai injection based on his real world[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2012, 37(18): 2710-2713.